股票CFDs僅限於MT5賬號類型。以上點差反映的是01/4/2020 – 30/6/2020 09:00AM - 21:00PM（格林尼治標準時間）間的加權平均值。雖然FxPro試圖在所有交易時間內提供有競爭力的點差，但客戶應注意這些點差可能會因潛在市場條件的影響而有所不同。以上內容僅供參考。建議客戶查看我們的經濟日曆中的重要新聞公告，這可能會導致點差擴大以及其他情況。

以上點差適用于正常外匯交易條件，根據“商業條款與條件”，FxPro有權根據市場條件對以上點差做調整。

Trade AbbVie Inc

AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.

The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.

Please note this is marketing communication, not recommendation or advice.

請注意，本材料只是一種市場傳播，不應被視為投資意見或建議。